According to the Department of Statistics Malaysia (DOSM), population with age 60 and above is increasing yearly and Malaysia is set to become a nation of the elderly by 2030, with citizens over 60 reaching 15.3% of the total population. This means 1 out of every 6 people will be over 60 years of age in 8 years' time.

This spells significant threat to Malaysia's healthcare industry and society in general, and escalates common, degenerative and chronic diseases and immune deficiencies - leading to disability, immobility and dependency and premature deaths amongst Malaysians. 

The future treatment for degenerative diseases will not be drugs nor surgeries, but cell therapy. University Kebangsaan Malaysia (UKM) which conducts research into regenerative medicine therapy (RMT) has shared that stem cells therapies are a viable avenue to restore organ functions via regeneration and functional repair of damaged tissues.

Malaysian company AlphaCelle has developed the world's first integrated stem cell therapy combining stems cells, high electric potential and exosomes. AlphaCelle sources stem cells ethically from umbilical cords of young and healthy women post-delivery from hospitals, ensuring the highest quality and energy mesenchymal stem cells (MSCs) available.

The company recently conducted public education workshops with their panel of medical practitioners to discuss the future of regenerative therapies.